ArticlePharmaceutics2023
Computational Modeling, High-Level Soluble Expression and In Vitro Cytotoxicity Assessment of Recombinant
Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 11 citations in OpenAlex.
- Possible Applications of Azurin, a Copper-Containing Protein, in Cancer Treatment: Prospects and Challenges.Current drug targets · 2026Review
- The Production of Recombinant Azurin fromInternational journal of molecular sciences · 2025Article
- Structural insights and predictive modelling of a novel anti-HER2 scFv and Leptulipin: a newly designed immunotoxin protein for HER2 positive cancers.Toxicology research · 2025Article
- Azurin a potent anticancer and antimicrobial agent isolated from a novel Pseudomonas aeruginosa strain.Scientific reports · 2025Article
- Unlocking the potential of tumor-targeting peptides in precision oncology.Oncology research · 2025Review
- Design and computational analysis of a novel Azurin-BR2 chimeric protein against breast cancer.Toxicology research · 2024Article
- Detection and molecular insights into the azurin gene expression post- gamma irradiation in P. aeruginosa.Archives of microbiology · 2024Article
- Design and computational analysis of a novel Leptulipin-p28 fusion protein as a multitarget anticancer therapy in breast cancer.Toxicology research · 2024Article
- Computational modeling study of IL-15-NGR peptide fusion protein: a targeted therapeutics for hepatocellular carcinoma.AMB Express · 2024Article
- Investigation of therapeutic potential of the Il24-p20 fusion protein against breast cancer: an in-silico approach.In silico pharmacology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 5 countries.
Funding
Abstract
Azurin is a natural protein produced by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.